VivoSeq
Other

Altitude Sickness

7

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Altitude Sickness is an early-stage landscape with 7 programs across 5 companies. The most active players are Kenvue Brands, Salix, Teva. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kenvue Brands

1 program

Phase 1S

Salix

1 program

Phase 3Teva logo

Teva

1 program

Phase 3A

Arbor Pharmaceuticals, Inc.

1 program

ApprovedGilead logo

Gilead

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy
Completed·—·Phase 1·NCT03154645·92 enrolled
NSAID RCT for Prevention of Altitude Sickness
Unknown status·NNaval Health Research Center·Phase 2·NCT01606527·300 enrolled
Altitude Sickness Prevention and Efficacy of Comparative Treatments
Completed·SStanford University·Phase 3·NCT02604173·103 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)